A protective effect of lower MHC-II expression in MOGAD.
J Neuroimmunol
; 391: 578351, 2024 Jun 15.
Article
in En
| MEDLINE
| ID: mdl-38703720
ABSTRACT
Myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) is a demyelinating central nervous system disorder. We aimed to uncover immune pathways altered in MOGAD to predict disease progression. Using nanostring nCounter technology, we analyzed immune gene expression in PBMCs from MOGAD patients and compare it with healthy controls (HCs). We found 35 genes that distinguished MOGAD patients and HCs. We then validated those results in a larger cohort including MS and NMOSD patients. Expressions of HLA-DRA was significantly lower in MOGAD patients. This reduction in HLA-DRA, correlated with a monophasic disease course and greater brain volume, enhancing our ability to predict MOGAD progression.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Myelin-Oligodendrocyte Glycoprotein
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Neuroimmunol
Year:
2024
Type:
Article
Affiliation country:
Israel